Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (487)	1/21/1998 1:07:00 AM
From: Bruce Russell	Read Replies (2) \| Respond to of 1580

Interestingly, Merck's asthma medication, Singulaire, is from a class of drugs that have caused liver damage. The FDA is being very slow to approve it. Merck doesn't bring unsafe drugs to market. From what I hear, this will be a significant advance in asthma therapy for a lot of people: one pill per day, instead of inhalers on demand. This could be one very big drug. Also, the Maxalt for migraine is the first oral migraine medication with the efficacy of an injectable. It will be a very big drug. These drugs need to get out of the gate fast.

To: Brian Malloy who wrote (487)	1/21/1998 3:53:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 1580

<<MRK tends not to have drugs pulled from the market once appproved as was the case with a Pfizer drug last year that was a newly vauted drug to help with diabetes. Unfortunately, it appeared that in the real world it was causing too much liver damage and a few deaths. The FDA pulled it.>> Umm, wrong company, wrong conclusion. WLA has a diabetes drug, Rezulin, currently on the market that now has a new warning label due to liver damage being observed, but the FDA didn't "pull it", it's still marketed. And PFE was not involved.